Would you get a jab?
Well, COVID-19 vaccines turned out to be much worse than the virus. A lot of people died as a result of the vaccine and most receivers deal with serious side effects.
Join Our Telegram channel here: https://t.me/TheTrueReporter
Wait… Things will get a lot worse in the future.
Get ready for your “twice-a-day” drug. It’s supposed to keep you healthy. Oh, you will be getting boosters till the end of time.
This was developed by Pfizer’s friendly experts.
Things can go terribly wrong at this point.
Imagine getting a Pfizer pill twice a day… Your body will turn into a dumpster.
Albert Bourla is Pfizer’s Chairman and CEO.
Success against #COVID19 will likely require both vaccines & treatments. We’re pleased to share we’ve started a Phase 2/3 study of our oral antiviral candidate—specifically designed to combat SARS-CoV-2—in non-hospitalized, low-risk adults: https://t.co/su5VtfbWPX
— AlbertBourla (@AlbertBourla) September 1, 2021
Check out the Press Release filled with details about the new “pill”:
First Participant Dosed in Phase 2/3 Study of Oral Antiviral Candidate in Non-Hospitalized Adults with COVID-19 Who Are at Low Risk of Severe Illness
New York, N.Y., September 1, 2021 – Pfizer Inc. (NYSE:PFE) today shared that the first participant has been dosed in a pivotal Phase 2/3 clinical trial to evaluate the safety and efficacy of PF-07321332 – an investigational orally administered protease inhibitor antiviral therapy designed specifically to combat COVID-19 – in non-hospitalized, symptomatic adult participants who have a confirmed diagnosis of SARS- CoV-2 infection and are not at increased risk of progressing to severe illness, which may lead to hospitalization or death.
The randomized, double-blind trial will enroll approximately 1,140 participants, who will receive PF- 07321332/ritonavir or placebo orally every 12 hours for five days.
Protease inhibitors, like PF-07321332, are designed to block the activity of the main protease enzyme that the coronavirus needs to replicate. Co-administration with a low dose of ritonavir is expected to help slow the metabolism, or breakdown, of PF-07321332 in order for it to remain in the body for longer periods of time at higher concentrations, thereby working continuously to help combat the virus. Ritonavir has previously been used in combination with other antivirals to similarly inhibit metabolism.
This study is part of a global clinical development program, consisting of multiple ongoing and planned clinical trials to evaluate this early-intervention, outpatient therapeutic candidate for potential use in a broad population of patients. The first registrational trial in this program, a pivotal Phase 2/3 study of PF- 07321332/ritonavir in non-hospitalized, symptomatic adult participants who have been diagnosed with SARS-CoV-2 infection and are at increased risk of progressing to severe illness, began enrollment in July 2021.
If successful, PF-07321332/ritonavir has the potential to address a significant unmet medical need, providing patients with a novel oral therapy that could be prescribed at the first sign of infection, without requiring hospitalization.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Pharmaceutical megacorporation pfizer is now developing a COVID pill that is meant to be taken alongside the COVID vaccines that have already made the company a staggering amount of money. The new pill is expected to be released by the end of the year and will be required to be taken twice per day.
“Success against #COVID19 will likely require both vaccines & treatments,” Pfizer CEO Albert Bourla said on Wednesday. “We’re pleased to share we’ve started a Phase 2/3 study of our oral antiviral candidate-specifically designed to combat SARS-CoV-2-in non-hospitalized, low-risk adults.”
Pfizer also put out a press release the same week that proclaimed, “If successful, [the drug] has the potential to address a significant unmet medical need, providing patients with a novel oral therapy that could be prescribed at the first sign of infection, without requiring hospitalization.” The company described the drug as an “investigational orally administered protease inhibitor antiviral therapy designed specifically to combat COVID–19 – in non–hospitalized, symptomatic adult participants who have a confirmed diagnosis of SARS–CoV–2 infection and are not at increased risk of progressing to severe illness, which may lead to hospitalization or death.”
Big corporations are excited about this PILL. Pfizer is really motivated to keep going.
Enter this boy from Singapore.
The 16-year-old is eligible for a $225,000 settlement after suffering a heart attack. He received the first dose of the Prizer BionTech vaccine. The Ministry of Health stated, “The myocarditis was likely a serious adverse event arising from the COVID-19 vaccine he received, which might have been aggravated by his strenuous lifting of weights and his high consumption of caffeine through energy drinks and supplements.”
Twice a day Covid pill by Pfizer pic.twitter.com/S5guXlcm7z
— Osler (@osler78) September 1, 2021
How can you restore your immunity and beat COVID-19?
Join Our Telegram channel here: https://t.me/TheTrueReporter
Source: The True Defender